The packaging machine is expected to increase the company’s production capabilities and help meet the growing demand of its customers for high-quality pharmaceutical products
Mikart, a US-based contract development and manufacturing organisation (CDMO), has purchased a new advanced Flexpack NF-150 Horizontal Sachet-Packaging Machine for clinical and commercial manufacturing packaging.
The company offers a range of services from development project work to commercial manufacturing for solid and liquid oral dosage forms.
FlexPack NF-150 Horizontal Sachet-Packaging machine is expected to increase the company’s production capabilities and deliver high-quality pharmaceutical products, the CDMO said.
The purchase of the equipment will allow the company to meet the increasing demands of its customers.
Mikart chief executive officer Micheal Kallelis said: “We believe that our investment in the Flexpack NF-150 marks a pivotal moment for Mikart’s capabilities expansion plan.
“The sachet packaging capabilities were done as a result of customer demand and will enhance our packaging capabilities, allowing us to deliver a wider packaging offering for the pharmaceutical products we manufacture.”
Mikart product development services vice-president Nazar Elkarim said: “We are excited to add the Flexpack NF 150 to our packaging capabilities.
“This machine will allow us to produce a wider variety of pouches, including single or twin sachets, and different shapes. This will help us to better meet the needs of our customers as our business continues to grow.”
The new investment intends to improve client demand for clinical and commercial scale sachet packaging capabilities with a broad range of product kinds and packaging designs.
Mikart’s existing packaging portfolio includes unit dose cups, blister packaging, pouch/foil strip packs, cartooning and tray packaging, and bottle filling.
Established in 1975, Mikart offers a full range of formulation, analytical, and manufacturing services to pharmaceutical companies for a complete and seamless development solution that lowers the time to market via clinical trials and commercial launches.
In January this year, the American firm announced the completion of its new liquids and suspensions suite in Atlanta, Georgia.
The investment was intended to increase liquid oral drug product development and manufacturing capabilities of complex formulations.